Skip to content

Diabetic Foot Ulcer and Wound Infection

Remote Glycemic Management for Patients With Diabetic Foot Ulcer and Wound Infection

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03827902
Enrollment
0
Registered
2019-02-04
Start date
2019-07-09
Completion date
2020-04-02
Last updated
2020-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Complications, Diabetic Foot Ulcer, Wound Infection

Brief summary

The goal of the study is to compare whether an integrated model of care between Foot Wound and Diabetes Clinic with use of remote glucose monitoring technology (Intervention Arm), as compared with usual care without the use of remote glucose monitoring technology (Control Arm), will result in 1) improved glycemic control, 2) improved ulcer and wound healing, 3) improved patient reported outcomes (PROs), 4) reduced long-term healthcare resource utilization, and 5) improved adherence to anti-glycemic therapy for patients with DFUWI and poor glycemic control over the course of a 6-month intervention period.

Detailed description

This is a two-arm non-randomized convenient pilot trial to assess impact of an active glycemic management model through remote glucose monitoring technology amongst patients with DFUWI and poor glycemic control at the Parkland Diabetes Foot & Wound clinic. The plan is to implement a remote glucose monitoring technology to facilitate improved glycemic management and control. A cellular enabled glucose meter that will upload blood glucose measurements to a cloud server accessible by providers who can remotely review glycemic trends and remotely provide patients with proactive recommendations for treatment adjustments will be used. Patients receiving services in the integrated care model (same day visits in the Foot Wound and Diabetes Clinics at Parkland) will be eligible for inclusion in the intervention arm which includes proactive glucose monitoring guided by remote glucose monitoring technology. Patients receiving usual care services (non-integrated care model clinic days where Foot Wound and Diabetes Clinic visits are on separate days) will be eligible for inclusion in the control arm. The expectation is that patients in the intervention arm will experience greater improvements in glycemic control, compared to the usual care model. The hypothesis is that improved glycemic control in these patients will result in faster healing of diabetic foot wound, infections or ulcers. The effectiveness of the technologically facilitated integrated model of care will be evaluated compared to the usual care using metrics for diabetic foot ulcers and wound healing, glycemic control, patient reported outcomes, health resource utilization and medication adherence after 6 months of intervention. The Telcare 2.0 BGM for remote self-blood glucose monitoring(FDA Cleared) will be used.

Interventions

DEVICETelcare 2.0 BGM

Blood glucose meter that uploads blood glucose measurements to a cloud server that providers can access and use to monitor patients' glycemic trends.

Sponsors

Parkland Health and Hospital System
CollaboratorOTHER
University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Type 2 Diabetes * 18 years and older * A1C greater than or equal to 8.5% within the preceding 6 months * A1C greater than 8% on day of enrollment * Active diabetic foot ulcer or wound receiving treatment in the Foot Wound clinic at Parkland (ulcer that meets University of Texas Classification Grade 1 or 2 of any stage)

Exclusion criteria

* Chronic osteomyelitis (even if completed active therapy) * Moderate/severe lower limb infection (per Infectious Diseases Society of America criteria) * Diabetic Foot Ulcer and Wound Infection on Charcot Foot * Any serious/unstable medical condition that interferes with treatment assignment * Ankle Brachial Index less than 0.7 or toe pressures less than 30mmHg * Unwilling to participate or receive injectable treatment or unable to keep appointments * Non-English or Non-Spanish speakers * Pregnant or planning to become pregnant

Design outcomes

Primary

MeasureTime frameDescription
Change in HbA1c6 monthsMean change in HbA1c from baseline to end of treatment

Secondary

MeasureTime frameDescription
Proportion of patients with emergency department visits6 monthsProportion of patients with emergency department visits following enrollment
Glycemic control6 monthsProportion of patients with lower A1C and insulin use
Foot ulcer and/or wound healing6 monthsComplete wound healing as defined by University of Texas Health System
Patient reported satisfaction with diabetes treatment6 monthsSelf-reported outcome assessment questionnaire using the Diabetes Treatment Satisfcation Questionnaire (DTSQ) \[Scale range 0-48\]; lower scores represent worse outcomes
Patient reported health status6 monthsSelf-reported outcome assessment questionnaires using the 5 level EQ-5D health status measure (EQ-5D-5L) \[Scale range 5-25\]; higher scores represent worse outcome
Proportion of days covered score6 monthsProportion of days covered score represents an indirect measure of medication adherence and represents the proportion of days medication was dispensed (numerator) over the total potential days the medication should have been dispensed (denominator)
Frequency of invasive procedures6 monthsTotal number and type of invasive procedures related to diabetic foot ulcer and or wound infection
Number of outpatient visits6 monthsTotal number of outpatient visits for general or specialized care (including virtual visits) during trial
Number of casts and boots used for treatment6 monthsTotal number of casts and boots used for treatment related to diabetic foot ulcer and or wound infection
Overall hospital incurred patient-specific cost6 monthsCost (in US $) of overall patient care for Parkland during study enrollment
Cost of glycemic management during study6 months• Cost of glycemic management during trial, including cost of encounters (including telephone and virtual visits), testing supplies, drug costs, technology costs specifically related to glycemic management
Proportion of patients with hospitalization6 monthsProportion of patients with hospitalization following enrollment

Other

MeasureTime frameDescription
Frequency of hypoglycemic events6 monthsComparison of frequency of severe hypoglycemic symptoms for usual care versus intervention arm

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026